Merck & Co Inc

NYSE:MRKUnited States

Nov 25, 2024

Show headlines and story abstract

• Jefferies Raises Merck Price Target to $150 From $149, Buy Rating Maintained, from 11:37AM ET on Monday Nov 25, 2024 by MT Newswires

  11:37AM ET on Monday Nov 25, 2024 by MT Newswires
  Companies Mentioned: MRK
  11:37 AM EST, 11/25/2024 (MT Newswires) -- Merck (MRK) has an average rating of overweight and mean price target of $131.26, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and r...

• Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Ahead of Key Inflation Data, from 8:26AM ET on Monday Nov 25, 2024 by MT Newswires

  8:26AM ET on Monday Nov 25, 2024 by MT Newswires
  Companies Mentioned: GLD, FAS, FAZ, IBB, IGM, IGV, SOXX, IVV, IWM, IYE, IYH, IYJ, IYK, IYW, BBWI, MRK, MS, QQQ, SPY, VDC, VHT, VIS, XLE, XLF, XLI, XLK, XLP, XLV, XLY, XSD, RTH, USO, SLV, XRT, EXI, RKLB, MOBX, BITO, UNG, EEM, EQT
  08:26 AM EST, 11/25/2024 (MT Newswires) -- The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.5% and the actively traded Invesco QQQ Trust (QQQ) advanced 0.6% in Monday's premarket activity, ahead of key inflation data due t...

• Merck Heart Disease Drug Meets Target in Phase 3 Study, from 7:10AM ET on Monday Nov 25, 2024 by MT Newswires

  7:10AM ET on Monday Nov 25, 2024 by MT Newswires
  Companies Mentioned: MRK
  07:10 AM EST, 11/25/2024 (MT Newswires) -- Merck (MRK) said Monday its experimental drug Winrevair, for pulmonary arterial hypertension, met primary endpoint in a phase 3 study. In the study, patients treated with Winrevair showed a statistically si...

• Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR(TM) (sotatercept-csrk) Met Primary Endpoint at Interim Analysis, from 6:45AM ET on Monday Nov 25, 2024 by Dow Jones

  6:45AM ET on Monday Nov 25, 2024 by Dow Jones
  Companies Mentioned: MRK
  
  Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.